01—Abstract
Summary
Summary of the 8-K filed November 18, 2024. Cited figures are marked; the original filing is the authoritative source.
On November 13, 2024, Cardinal Health, Inc. (CAH) entered into an underwriting agreement with BofA Securities, J.P.
Morgan Securities, and Wells Fargo Securities, acting as representatives of the underwriters, for the sale of $2.9 billiona in aggregate principal amount of senior notes across four tranches. The offering was made under the company's effective Form S-3 shelf registration (No. 333-268237). The offering spans maturities from 2026 to 2054: $500 million of 4.700% notes due 2026, $750 million of 5.000% notes due 2029, $1.0 billion of 5.350% notes due 2034, and $650 million of 5.750% notes due 2054.
The 2034 tranche is the largest, and the 2054 tranche provides long-dated financing at the highest coupon in the deal. The filing reflects a debt issuance rather than an equity raise, so it does not dilute existing shareholders.
The 8-K itself does not disclose the use of proceeds, pricing details, or the company's leverage targets. Investors should review the full Underwriting Agreement (Exhibit 1.1) and the company's subsequent disclosures for the intended use of proceeds, such as refinancing existing debt, and for the effect on interest expense and the balance sheet.
02—Key points
Key Highlights
- Cardinal Health sold $2.9 billion in aggregate principal amount of senior notes under an underwriting agreement dated November 13, 2024.
- Four tranches were issued: $500M 4.700% due 2026, $750M 5.000% due 2029, $1.0B 5.350% due 2034, and $650M 5.750% due 2054.
- The offering was executed under the company's effective Form S-3 shelf registration (No. 333-268237).
- BofA Securities, J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC acted as representatives of the underwriters.
- The debt issuance adds to the company's long-term debt obligations, with annual coupon payments that will increase interest expense over the life of the notes.
- The 2034 notes are the largest tranche at $1.0 billion, and the 2054 notes carry the highest coupon at 5.750%, reflecting the long-dated maturity.
- The filing does not disclose use of proceeds, so investors should consult the full Underwriting Agreement and subsequent company disclosures.
03—Questions
Frequently Asked Questions
How much debt did Cardinal Health raise in this offering?
Cardinal Health sold $2.9 billion in aggregate principal amount of senior notes across four tranches: $500 million due 2026, $750 million due 2029, $1.0 billion due 2034, and $650 million due 2054.
What are the interest rates on the notes?
The notes carry fixed coupons of 4.700% (2026), 5.000% (2029), 5.350% (2034), and 5.750% (2054). Annual coupon payments on the full $2.9 billion would be roughly $150 million across the four tranches, before considering any timing or payment-schedule details in the indenture.
Was this offering dilutive to shareholders?
No. This was a debt offering of senior notes, not an issuance of common stock, so it does not directly dilute existing shareholders. It does increase the company's debt load and future interest expense.
Under what registration was the offering made?
The offering was made pursuant to Cardinal Health's effective Form S-3 shelf registration statement (Registration Statement No. 333-268237), previously filed with the SEC.
Where can investors find more details on the terms of the offering?
The full terms are in the Underwriting Agreement, filed as Exhibit 1.1 to the 8-K, and in the related indenture and prospectus supplement. The 8-K summary does not cover use of proceeds, pricing, or redemption provisions.
04—Continue